Acute Kidney Injury Treatment Market Expected to Witness a High CAGR of 8% from 2024 to 2029
The acute kidney injury (AKI) treatment market is experiencing steady growth, with a CAGR projected at approximately 8% during the forecast period. The market is driven by several key factors, including the increasing incidences of AKI due to chronic diseases like diabetes and hypertension, the rising geriatric population, and the growing number of surgeries and hospitalizations. Additionally, the expansion of healthcare infrastructure and the increasing availability of advanced diagnostic technologies contribute to market growth. However, high treatment costs and limited access to specialized healthcare facilities in certain regions act as major restraints. To learn more about the research report, download a sample report.
Acute kidney injury (AKI) refers to the sudden decline in kidney function, often caused by reduced blood flow, direct damage to the kidneys, or blockages. This condition causes a buildup of waste products in the blood and disrupts the balance of fluids, electrolytes, and acid-base levels in the body. Treatment for AKI generally involves addressing the underlying cause, managing symptoms, and supporting kidney recovery through interventions like dialysis or medication. Early detection and prompt treatment are critical to improving outcomes and preventing long-term damage.
To learn more about this report, download the PDF brochure
Significant Factor Driving Demand: Aging Population and Increased Hospitalizations
A crucial factor driving the demand in the acute kidney injury treatment market is the growing aging population. Older adults are more prone to developing AKI due to age-related declines in kidney function, as well as their higher susceptibility to chronic diseases such as cardiovascular conditions, diabetes, and hypertension. Additionally, this demographic group undergoes more frequent surgeries and hospitalizations, which are known risk factors for AKI, particularly when involving complex procedures like heart surgeries and organ transplants. According to the United Nations, the global aged population will nearly double by 2050, significantly raising the burden of chronic diseases and driving the demand for specialized treatment options. The healthcare industry is increasingly focused on early intervention and managing the heightened AKI risk among elderly patients, further boosting the need for effective therapies.
Emerging Trend: Biomarkers for Early Detection of AKI
An emerging trend enhancing the AKI treatment market is the development of biomarkers for early detection and diagnosis. Traditional diagnostic methods, such as serum creatinine levels, are often unreliable in identifying AKI at its onset, leading to delayed treatment and poorer patient outcomes. Biomarkers like Neutrophil Gelatinase-Associated Lipocalin (NGAL), Cystatin C, and Kidney Injury Molecule-1 (KIM-1) are gaining attention for their potential to detect AKI earlier and more accurately. While NGAL and Cystatin C are starting to see use in some clinical settings for early identification of AKI, KIM-1 is still primarily in research and clinical trial stages. The integration of these biomarkers into clinical practice is expected to enhance patient outcomes by allowing for timely interventions and more effective management of kidney health, reflecting a broader shift toward precision medicine and personalized healthcare in AKI treatment.
To learn more about this report, download the PDF brochure
Competitive Landscape Analysis
The global acute kidney injury treatment market is marked by the presence of established and emerging market players such as AM-Pharma; Astellas Pharma Inc.; Asahi Kasei Medical Co. Ltd.; Baxter Corporation; Novartis, Pfizer Inc.; Merck & Co.; NIPRO Medical; NIKKISO; Fresenius Medical Care AG & Co. KGaA; among others. Some of the key strategies adopted by market players include product innovation and development, strategic partnerships and collaborations, and geographic expansion.
Acute Kidney Injury Treatment Market Scope
|
Report Scope |
Details |
|
Base Year Considered |
2023 |
|
Historical Data |
2022 - 2023 |
|
Forecast Period |
2024 - 2029 |
|
Growth Rate |
CAGR 8% |
|
Segment Scope |
Treatment, Type and End User |
|
Regional Scope |
|
|
Key Companies Mapped |
AM-Pharma; Astellas Pharma Inc.; Asahi Kasei Medical Co. Ltd.; Baxter Corporation; Novartis, Pfizer Inc.; Merck & Co.; NIPRO Medical; NIKKISO; and Fresenius Medical Care AG & Co. KGaA among others |
|
Report Highlights |
Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis |
Key Strategic Questions Addressed
-
What is the market size & forecast of the acute kidney injury treatment market?
-
What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the acute kidney injury treatment market?
-
What are the key trends defining the market?
-
What are the major factors impacting the market?
-
What are the opportunities prevailing in the market?
-
Which region has the highest share in the global market?
-
Which region is expected to witness the highest growth rate in the next 5 years?
-
Who are the major players operating in the market?
-
What are the key strategies adopted by players?
- Introduction
- Introduction
- Market Scope
- Market Definition
- Segments Covered
- Regional Segmentation
- Research Timeframe
- Currency Considered
- Study Limitations
- Stakeholders
- List of Abbreviations
- Key Conferences and Events (2023-2024)
- Research Methodology
- Secondary Research
- Primary Research
- Market Estimation
- Bottom-Up Approach
- Top-Down Approach
- Market Forecasting
- Executive Summary
- Acute Kidney Injury Treatment Market Snapshot (2023-2029)
- Segment Overview
- Regional Snapshot
- Competitive Insights
- Market Overview
- Market Dynamics
- Drivers
- Increasing prevalence of chronic diseases
- Increasing aging population
- Higher rates of hospitalization and surgeries
- Advancements in diagnostic technologies
- Increased awareness and focus on early detection and treatment of AKI
- Restraints
- High treatment costs
- Limited access to specialized healthcare facilities in rural and underserved areas
- Variability in clinical guidelines and practices across different regions
- Opportunities
- Development of novel biomarkers for early AKI detection
- Integration of telemedicine and remote monitoring technologies
- Key Market Trends
- Increased research and development in regenerative medicine for kidney repair
- Adoption of AI & M/L in diagnostics and treatment planning
- Unmet Market Needs
- Industry Speaks
- Regulatory Analysis
- Drivers
- Market Dynamics
- Global Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), By Treatment, USD Million
- Introduction
- Drug Therapy
- Dialysis
- Global Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), By Type, USD Million
- Introduction
- Pre-renal Injury
- Intrinsic Renal Injury
- Post-renal Injury
- Global Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), By End User, USD Million
- Introduction
- Hospitals
- Ambulatory Surgical Centers
- Others
- Global Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), By Region, USD Million
- Introduction
- Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), By Country, USD Million
- US
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Canada
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), By Country, USD Million
- UK
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Germany
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- France
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Italy
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Spain
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Rest of Europe
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Asia Pacific (APAC) Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), By Country, USD Million
- China
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Japan
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- India
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Rest of Asia Pacific
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Latin America (LATAM) Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), USD Million
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- Middle East & Africa (MEA) Acute Kidney Injury Treatment Market Size & Forecast (2022-2029), USD Million
- Market Size & Forecast, By Treatment (USD Million)
- Market Size & Forecast, By Type (USD Million)
- Market Size & Forecast, By End User (USD Million)
- China
- UK
- US
- Competitive Landscape
- Key Players and their Competitive Positioning
- Key Player Comparison
- Segment-wise Player Mapping
- Market Share Analysis (2023)
- Company Categorization Matrix
- Dominants/Leaders
- New Entrants
- Emerging Players
- Innovative Players
- Key Strategies Assessment, By Player (2022-2024)
- New Product Launches
- Partnerships, Agreements, & Collaborations
- Mergers & Acquisitions
- Geographic Expansion
- Key Players and their Competitive Positioning
- Company Profiles*
(Business Overview, Financial Performance**, Products Offered, Recent Developments)
- AM-Pharma
- Astellas Pharma Inc.
- Asahi Kasei Medical Co. Ltd.
- Baxter Corporation
- Novartis
- Pfizer Inc.
- Merck & Co.
- NIPRO Medical
- NIKKISO
- Fresenius Medical Care AG & Co. KGaA
- Other Prominent Players
The study has been compiled based on extensive primary and secondary research.
Secondary Research (Indicative List)
Primary Research
To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.
Supply Side Stakeholders:
- Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers
- Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants
Demand Side Stakeholders:
- Hospitals, Ambulatory Surgical Centers, and Others
Breakdown of Primary Interviews
Market Size Estimation
Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts
Data Triangulation
Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data
